Physician profile
Todd Wilkinson
NPI 1669694113
$1,246.09
in general payments reported to CMS, 2019-2025
14 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.14 · 2023: $199 · 2024: $416 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.48 | 2023-2025 | Skyrizi |
| Amgen INC. | $187.27 | 2023-2025 | Otezla |
| Janssen Biotech, INC. | $147.55 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $120.03 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $118.49 | 2022-2025 | Ilumya |
| Ucb, INC. | $64.91 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $57.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $45.75 | 2024-2025 | |
| Allergan, INC. | $45.10 | 2022 | |
| Lilly USA, LLC | $34.27 | 2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $29.99 | 2025 | Dupixent |
| Dilon Technologies, INC. | $29.64 | 2025 | Hemoblast Bellows |
| Botanix Sb INC | $26.64 | 2025 | Sofdra |
| Leo Pharma INC. | $24.36 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.